Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pyoderma gangrenosum: Clofazimine therapy].

J Beurey, M Weber, J L Delrous

    Annales De Dermatologie Et De Venereologie
    |October 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Clofazimine effectively treated pyoderma gangrenosum in two patients. This study highlights Clofazimine

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Connubial dermatitis from phenylmercuric nitrate.

    Contact dermatitis·1996
    Same author

    [Fixed pigmented erythema caused by levamisole administration].

    Annales de dermatologie et de venereologie·1994
    Same author

    Deletions of the COL4A5 gene in patients with Alport syndrome.

    Kidney international·1992
    Same author

    Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production.

    British journal of haematology·1992
    Same author

    [Expert evaluation in bony injuries of the spine].

    Zeitschrift fur Orthopadie und ihre Grenzgebiete·1992
    Same author

    [Rotational stability of angiography catheters].

    Zeitschrift fur Kardiologie·1992

    Area of Science:

    • Dermatology
    • Immunology

    Background:

    • Pyoderma gangrenosum (PG) is a rare, ulcerative neutrophilic dermatosis.
    • PG can be associated with systemic conditions like inflammatory bowel disease and monoclonal gammopathies.
    • Treatment options for PG can be limited, necessitating exploration of alternative therapies.